keyword
MENU ▼
Read by QxMD icon Read
search

RECIST

keyword
https://www.readbyqxmd.com/read/29350464/predictors-of-response-progression-free-survival-and-overall-survival-using-nant-response-criteria-v1-0-in-relapsed-and-refractory-high-risk-neuroblastoma
#1
Judith G Villablanca, Lingyun Ji, Adi Shapira-Lewinson, Araz Marachelian, Hiroyuki Shimada, Randall A Hawkins, Miguel Pampaloni, Hollie Lai, Fariba Goodarzian, Richard Sposto, Julie R Park, Katherine K Matthay
PURPOSE: The New Approaches to Neuroblastoma Therapy Response Criteria (NANTRC) were developed to optimize response assessment in patients with recurrent/refractory neuroblastoma. Response predictors and associations of the NANTRC version 1.0 (NANTRCv1.0) and prognostic factors with outcome were analyzed. METHODS: A retrospective analysis was performed of patients with recurrent/refractory neuroblastoma enrolled from 2000 to 2009 on 13 NANT Phase 1/2 trials. NANTRC overall response integrated CT/MRI (Response Evaluation Criteria in Solid Tumors [RECIST]), metaiodobenzylguanidine (MIBG; Curie scoring), and percent bone marrow (BM) tumor (morphology)...
January 19, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29350109/tertiary-care-experience-of-sorafenib-in-the-treatment-of-progressive-radioiodine-refractory-differentiated-thyroid-carcinoma-a-korean-multicenter-study
#2
Mijin Kim, Tae Hyuk Kim, Dong Yeob Shin, Dong-Jun Lim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, YoungKee Shong, Bo Hyun Kim, Won Gu Kim
BACKGROUND: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). In this study, we evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results with those of the DECISION trial. We also evaluated the clinical features associated with better clinical outcomes after sorafenib treatment. METHODS: This multicenter, retrospective cohort study evaluated 98 patients with progressive RAI-refractory DTC who were treated with sorafenib in six tertiary hospitals in Korea...
January 19, 2018: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29346507/activity-and-safety-of-afatinib-in-a-window-pre-operative-eortc-study-in-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-scchn
#3
J P Machiels, P Bossi, J Menis, M Lia, C Fortpied, Y Liu, R Lhommel, M Lemort, S Schmitz, S Canevari, L De Cecco, M Guzzo, R Bianchi, P Quattrone, F Crippa, T Duprez, Y Lalami, M Quiriny, N de Saint Aubain, P M Clement, R Coropciuc, E Hauben, L F Licitra
Background: To investigate the activity and safety of afatinib in the pre-operative treatment of squamous cell carcinoma of the head and neck (SCCHN). Patients and methods: This study was an open-label, randomized, multicenter, phase II window of opportunity trial. Treatment-naïve SCCHN patients selected for primary curative surgery were randomized (5:1 ratio) to receive afatinib during 14 days (day -15 until day -1) before surgery (day 0) or no treatment. Tumor biopsies, 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and magnetic resonance imaging (MRI) were performed at diagnosis and just before surgery...
January 15, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29344713/prognostic-factors-in-overall-survival-of-patients-with-unresectable-intrahepatic-cholangiocarcinoma-treated-by-means-of-yttrium-90-radioembolization-results-in-therapy-na%C3%A3-ve-patients
#4
P Reimer, M K Virarkar, M Binnenhei, M Justinger, M R Schön, K Tatsch
INTRODUCTION: To investigate prognostic factors in unresectable intrahepatic cholangiocarcinoma (ICC) therapy-naïve patients after yttrium-90 (Y-90) radioembolization (RE) therapy. MATERIALS AND METHODS: Between 2005 and 2016, 21 patients with ICC were treated with Y-90 RE only and their survival data were analyzed. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RESULT: The overall median survival was 15 months...
January 17, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29341833/immune-modified-response-evaluation-criteria-in-solid-tumors-imrecist-refining-guidelines-to-assess-the-clinical-benefit-of-cancer-immunotherapy
#5
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S Chen, Jedd D Wolchok
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29337640/molecular-determinants-of-response-to-anti-programmed-cell-death-pd-1-and-anti-programmed-death-ligand-pd-l-ligand-1-blockade-in-patients-with-non-small-cell-lung-cancer-profiled-with-targeted-next-generation-sequencing
#6
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman, Travis Hollmann, Kurt A Schalper, Justin F Gainor, Ronglai Shen, Ai Ni, Kathryn C Arbour, Taha Merghoub, Jedd Wolchok, Alexandra Snyder, Jamie E Chaft, Mark G Kris, Charles M Rudin, Nicholas D Socci, Michael F Berger, Barry S Taylor, Ahmet Zehir, David B Solit, Maria E Arcila, Marc Ladanyi, Gregory J Riely, Nikolaus Schultz, Matthew D Hellmann
Purpose Treatment of advanced non-small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of patients. Clinically available tools to optimize use of ICIs and understand the molecular determinants of response are needed. Targeted next-generation sequencing (NGS) is increasingly routine, but its role in identifying predictors of response to ICIs is not known. Methods Detailed clinical annotation and response data were collected for patients with advanced non-small-cell lung cancer treated with anti-programmed death-1 or anti-programmed death-ligand 1 [anti-programmed cell death (PD)-1] therapy and profiled by targeted NGS (MSK-IMPACT; n = 240)...
January 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29334722/comparison-of-the-morphologic-criteria-recist-and-metabolic-criteria-eortc-and-percist-in-tumor-response-assessments-a-pooled-analysis
#7
Hong Deok Kim, Bum Jun Kim, Hyeong Su Kim, Jung Han Kim
Background/Aims: The Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) or European Organization for Research and Treatment of Cancer (EORTC) criteria are used to assess metabolic tumor responses. However, tumor responses have shown considerable discrepancies between the morphologic criteria (Response Evaluation Criteria in Solid Tumors [RECIST]) and metabolic criteria. We performed this pooled study to compare the RECIST and metabolic criteria in the assessment of tumor responses...
January 17, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29332608/concealed-complete-response-in-melanoma-patients-under-therapy-with-immune-checkpoint-inhibitors-two-case-reports
#8
Stefan Schliep, Abbas Agaimy, Alexander Cavallaro, Franklin Kiesewetter, Gerold Schuler, Lucie Heinzerling
BACKGROUND: The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first time that patients were completely free of viable tumor. CASE PRESENTATION: Two patients with metastatic melanoma were treated with immune checkpoint inhibitors (ipilimumab/ nivolumab) and progressive metastases were detected on CT-scans performed shortly before histologic examinations...
January 15, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29327075/phase-ii-study-of-sorafenib-combined-with-concurrent-hepatic-arterial-infusion-of-oxaliplatin-5-fluorouracil-and-leucovorin-for-unresectable-hepatocellular-carcinoma-with-major-portal-vein-thrombosis
#9
Min-Ke He, Ru-Hai Zou, Qi-Jiong Li, Zhong-Guo Zhou, Jing-Xian Shen, Yong-Fa Zhang, Zi-Shan Yu, Li Xu, Ming Shi
BACKGROUND: Sorafenib is recommended for the first-line treatment of advanced hepatocellular carcinoma (HCC). However, the median progression-free survival (PFS) of patients with HCC and major portal vein tumor thrombosis treated with sorafenib monotherapy is no more than 3 months. A prospective single-arm phase II study was conducted to determine whether adding hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin to sorafenib could improve on these results...
January 11, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29326419/evaluation-of-multislice-spiral-computed-tomography-perfusion-imaging-for-the-efficacy-of-preoperative-concurrent-chemoradiotherapy-in-middle-aged-and-elderly-patients-with-locally-advanced-gastric-cancer
#10
Jian-Xiao Liang, Xiu-Juan Bi, Xiao-Mei Li, Zhen-Li Gao, Feng Suo, En-Gang Cui, Hong-Fu Li, Hai-Lian Lv
BACKGROUND This study aimed to investigate the predictive value of multislice spiral computed tomography (MSCT) perfusion imaging for the efficacy of preoperative concurrent chemoradiotherapy (CCRT) in middle-aged and elderly patients with locally advanced gastric cancer (LAGC). MATERIAL AND METHODS One-hundred twenty-six middle-aged and elderly patients with LAGC were selected. MSCT was performed before and after CCRT to obtain perfusion parameters: blood flow volume (BF), blood volume (BV), mean transit time (MTT), and permeability surface (PS)...
January 12, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29326281/evaluation-of-overall-response-rate-and-progression-free-survival-as-potential-surrogate-endpoints-for-overall-survival-in-immunotherapy-trials
#11
Sirisha L Mushti, Flora Mulkey, Rajeshwari Sridhara
PURPOSE: With the approval of immunotherapies for a variety of indications, methods to assess treatment benefit addressing the response patterns observed are important. We evaluated RECIST criteria based objective response rate (ORR) and progression-free survival (PFS) as potential surrogate endpoints of overall survival (OS), and explored a modified definition of PFS by altering the threshold percentage determining disease progression to assess the association with survival benefit in immunotherapy trials...
January 11, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29313279/a-phase-1-study-of-parp-inhibitor-abt-767-in-advanced-solid-tumors-with-brca1-2-mutations-and-high-grade-serous-ovarian-fallopian-tube-or-primary-peritoneal-cancer
#12
Diane A J van der Biessen, Jourik A Gietema, Maja J A de Jonge, Ingrid M E Desar, Martha W den Hollander, Matthew Dudley, Martin Dunbar, Robert Hetman, Camille Serpenti, Hao Xiong, Rajendar K Mittapalli, Kirsten M Timms, Peter Ansell, Christine K Ratajczak, Stacie Peacock Shepherd, Carla M L van Herpen
Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients received ABT-767 monotherapy orally until disease progression or unacceptable toxicity. Dose was escalated from 20 mg once daily to 500 mg twice daily (BID). Dose-limiting toxicities, recommended phase 2 dose (RP2D), food effect, objective response rate, and biomarkers predicting response were determined...
January 8, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29306769/phase-ii-trial-of-ipilimumab-in-melanoma-patients-with-preexisting-humoural-immune-response-to-ny-eso-1
#13
G M Haag, I Zoernig, J C Hassel, N Halama, J Dick, N Lang, L Podola, J Funk, C Ziegelmeier, S Juenger, M Bucur, L Umansky, C S Falk, A Freitag, I Karapanagiotou-Schenkel, P Beckhove, A Enk, D Jaeger
BACKGROUND: Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. PATIENTS AND METHODS: Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks...
January 4, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29301831/efficacy-safety-and-pharmacokinetics-of-axitinib-in-nasopharyngeal-carcinoma-a-preclinical-and-phase-2-correlative-study
#14
Edwin P Hui, Brigette B Y Ma, Herbert Loong, Frankie Mo, Leung Li, Ann D King, Ki Wang, Anil T Ahuja, Charles Ml Chan, Connie Wc Hui, Chi-Hang Wong, Anthony Tc Chan
PURPOSE: We hypothesized that axitinib is active with improved safety profile in nasopharyngeal carcinoma (NPC). EXPERIMENTAL DESIGN: We evaluated axitinib in preclinical models of NPC, and studied its efficacy in a phase 2 clinical trial in recurrent or metastatic NPC patients who progressed after at least one line of prior platinum-based chemotherapy. We excluded patients with local recurrence or vascular invasion. Axitinib was started at 5 mg twice-daily in continuous 4-weeks cycles...
January 4, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29299358/pacritinib-to-inhibit-jak-stat-signaling-in-refractory-metastatic-colon-and-rectal-cancer
#15
Thomas Regenbogen, Ling Chen, Kathryn Trinkaus, Andrea Wang-Gillam, Benjamin R Tan, Manik Amin, Katrina S Pedersen, Haeseong Park, Rama Suresh, Kian-Huat Lim, Emily Ratchford, Amberly Brown, A Craig Lockhart
Background: Treatment options for patients with refractory colorectal cancer are limited and typically provide a chance of only modest benefit. The goal of this study was to evaluate the benefit of inhibiting the JAK/STAT inflammatory pathway with single agent pacritinib in patients with metastatic refractory colorectal adenocarcinoma. Methods: A single arm institutional trial was initiated and enrolled patients with metastatic colorectal cancer refractory to at least two standard lines of treatment...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29299351/a-phase-2-trial-of-personalized-cytotoxic-therapy-based-on-tumor-immunohistochemistry-in-previously-treated-metastatic-pancreatic-cancer-patients
#16
Ramesh K Ramanathan, Glen J Weiss, Richard G Posner, N V Rajeshkumar, Gayle Jameson, Meraj Aziz, Antje Hoering, Vanessa Bolejack, Anirban Maitra, Monica Fulk, Edward C Stites, William S Hlavacek, Zoran Gatalica, Joanne Xiu, Manuel Hidalgo, Daniel D Von Hoff, Michael T Barrett
Background: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies. Methods: Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29297204/role-of-intravoxel-incoherent-motion-mri-in-early-assessment-of-the-response-of-esophageal-squamous-cell-carcinoma-to-chemoradiotherapy-a-pilot-study
#17
Huanhuan Zheng, Wei Ren, Xia Pan, Qinglei Zhang, Baorui Liu, Song Liu, Jian He, Zhengyang Zhou
BACKGROUND: Since definitive concurrent chemoradiotherapy (CRT) is standard therapy for inoperable esophageal squamous cell carcinoma (ESCC), early evaluation of treatment response is crucial for patients and would be useful in assessing response, especially in patients with severe side effects. PURPOSE: To explore the feasibility of intravoxel incoherent motion (IVIM) MRI in the early assessment of treatment response to CRT. STUDY TYPE: Prospective...
January 3, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29290959/circulating-tumor-cells-potential-markers-of-minimal-residual-disease-in-ovarian-cancer-a-study-of-the-ovcad-consortium
#18
Eva Obermayr, Natalia Bednarz-Knoll, Beatrice Orsetti, Heinz-Ulrich Weier, Sandrina Lambrechts, Dan Cacsire Castillo-Tong, Alexander Reinthaller, Elena Ioana Braicu, Sven Mahner, Jalid Sehouli, Ignace Vergote, Charles Theillet, Robert Zeillinger, Burkhard Brandt
Purpose: In 75% of ovarian cancer patients the tumor mass is completely eradicated by established surgical and cytotoxic treatment; however, the majority of the tumors recur within 24 months. Here we investigated the role of circulating tumor cells (CTCs) indicating occult tumor load, which remains inaccessible by established diagnostics. Experimental design: Blood was taken at diagnosis (baseline samples, n = 102) and six months after completion of adjuvant first-line chemotherapy (follow-up samples; n = 78)...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29286192/combination-of-pegylated-liposomal-doxorubicin-plus-gemcitabine-in-heavily-pretreated-metastatic-breast-cancer-patients-long-term-results-from-a-single-institution-experience
#19
Patricia Martin-Romano, Iosune Baraibar, Jaime Espinós, Jairo Legaspi, Jose M López-Picazo, Jose Manuel Aramendía, Oscar A Fernández, Marta Santisteban
The combination of Pegylated Liposomal Doxorubicin (PLD) plus Gemcitabine (GEM) has been previously investigated in the treatment of metastatic breast cancer (MBC). PLD is a doxorubicin formulation with prolonged circulation time and better tissue distribution. GEM is a nucleoside analog with nonoverlapping toxicity compared to PLD. The aim of our study was to assess efficacy, toxicity, and long-term outcome of this combination. Patients with heavily treated MBC were retrospectively analyzed. Chemotherapy consisted of PLD 25 mg/m2 and GEM 800 mg/m2 day 1, on a three-week schedule...
December 29, 2017: Breast Journal
https://www.readbyqxmd.com/read/29285651/a-long-term-survival-case-treated-with-conversion-surgery-following-chemotherapy-after-diagnostic-metastasectomy-for-pancreatic-cancer-with-synchronous-liver-metastasis
#20
Mitsuhiro Shimura, Masamichi Mizuma, Hiroki Hayashi, Akiko Mori, Tomoyoshi Tachibana, Tatsuo Hata, Masahiro Iseki, Tatsuyuki Takadate, Kyohei Ariake, Shimpei Maeda, Hideo Ohtsuka, Naoaki Sakata, Takanori Morikawa, Kei Nakagawa, Takeshi Naitoh, Takashi Kamei, Fuyuhiko Motoi, Michiaki Unno
BACKGROUND: Pancreatic cancer with distant metastases is classified as "unresectable," for which the standard treatment is systemic chemotherapy. The effectiveness of radical resection for pancreatic cancer with distant metastases is unknown. Here, we report a case of long term survival treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. CASE PRESENTATION: A 73-year-old man was referred to our hospital to examine and treat for cancer of the pancreatic body...
December 29, 2017: Surgical Case Reports
keyword
keyword
18088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"